Browse All

Current Filters

CLEAR FILTER x

TITLE

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study

Author:Bermel, Robert   Killestein, Joep   Berger, Thomas   Brochet, Bruno   Carroll, William   Freedman, Mark   Holmoy, Trygve   Karabudak, Rana   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Vollmer, Timothy   Buffels, Regine   Kadner, Karen   Bortolami, Oscar   Hartung, Hans-Peter   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.003  

Author Institution:Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria  University of Bordeaux, Bordeaux, France, Bordeaux, France  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Ottawa, ON, Canada  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Centre d’Esclerosi Mútiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA , Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Toulon, France  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Department of Neurology, UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Dusseldorf, Germany  

Retrospective comparison clinical presentation and outcome of Natalizumab and Fingolimod-associated PML

Author:Bernard-Valnet, Raphael   Blant, Julie   De Rossi, Nicola   Schroeder, Christoph   Maurousset, Aude   Krämer, Markus   Kume, Kodai   Misu, Tatsuro   Ouallet, Jean   Pallix Guyot, Maud   Gold, Ralf   Gerevini, Simonetta   Ayzenberg, Ilya   Du Pasquier, Renaud   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.004  

Author Institution:Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland  Regional Multiple Sclerosis Center, Montichiari, Italy  St. Josef-Hospital, Ruhr University , Bochum, Germany  Centre hospitalier régional universitaire de Tours, Hôpital Bretonneau, Tours, France  Alfried Krupp von Bohlen und Halbach Hospital, Essen, Germany  Research Institute for Radiation Biology and Medicine, Hiroshima , Japan  Tohoku University Hospital, Tohoku, Japan  CHU de Bordeaux Pellegrin Tripode, Bordeaux, France  Centre Hospitalier Régional d'Orléans, Orléans, France  St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany  Papa Giovanni XXIII Hospital, Bergamo, Italy  

Evobrutinib therapeutic response is associated with an increase in the number and maturation of peripheral and central classical dendritic cells

Author:Clemente, Diego   Serrano-Regal, Mari Paz   Calahorra, Leticia   Alonso-García, Inmaculada   Boschert Shafaatian, Ursula   Haselmayer, Philipp   Ortega, Cristina   Machín-Díaz, Isabel   Camacho-Toledano, Celia   García-Arocha, Jennifer   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.005  

Author Institution:1Neuroimmuno-Repair Group. Research Unit. Hospital Nacional de Parapléjicos-SESC, Toledo, Spain  2Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Geneva, Switzerland  3Merck KGaA, Darmstadt, Germany , Darmstadt, Germany  

Lack of B-cell Depletion with Ocrelizumab

Author:Saldivar, Sergio   Freedman, Mark   Rush, Carolina   Brooks, John   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.006  

Author Institution:The Ottawa Hospital Research Institute, Ottawa, ON, Canada  

Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis

Author:Cree, Bruce A. C.   Danese, Silvio   Wolf, Douglas C.   Alekseeva, Olga   Charles, Lorna   Petersen, AnnKatrin   Sheffield, James K.   Cheng, Chun-Yen   Riolo, Jon V.   Silva, Diego   Lublin, Fred D.   Rubin, David T.   Cohen, Jeffrey A.   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.007  

Author Institution:Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  Humanitas University, Milan, Italy, Milan, Italy  Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, Atlanta, GA  Nizhegorodskaya Regional Clinical, Nizhegorodskaya oblast' Russia, Nizhegorodskaya oblast' , Russian Federation  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Mount Sinai Medical Center, New York, New York, New York, NY  University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, Chicago, IL  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH